Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection
Author: ["Susanna K. Elledge","Xin X. Zhou","James R. Byrnes","Alexander J. Martinko","Irene Lui","Katarina Pance","Shion A. Lim","Jeff E. Glasgow","Anum A. Glasgow","Keirstinne Turcios","Nikita S. Iyer","Leonel Torres","Michael J. Peluso","Timothy J. Henrich","T
Publication: Nature Biotechnology
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Current serology tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies mainly take the form of enzyme-linked immunosorbent assays, chemiluminescent microparticle immunoassays or lateral flow assays, which are either laborious, expensive or lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost, solution-based assay to detect antibodies in serum, plasma, whole blood and to a lesser extent saliva, using rationally designed split luciferase antibody biosensors. This new assay, which generates quantitative results in 30 min, substantially reduces the complexity and improves the scalability of coronavirus disease 2019 (COVID-19) antibody tests. This assay is well-suited for point-of-care, broad population testing, and applications in low-resource settings, for monitoring host humoral responses to vaccination or viral infection. A rapid, split luciferase test for SARS-CoV-2 antibodies in blood and saliva compatible with lyophilization and use in low-resource settings.
Cite this article
Elledge, S.K., Zhou, X.X., Byrnes, J.R. et al. Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nat Biotechnol (2021). https://doi.org/10.1038/s41587-021-00878-8
